Moderna to Present at Upcoming Investor Conferences
25 September 2019 - 10:00PM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced its participation in the following
upcoming investor conferences:
- 2019 Cantor Fitzgerald Global Healthcare Conference in
New York City on Thursday, October 3, 2019 at 10:05 a.m. ET.
- Chardan’s 3rd Annual Genetic Medicines Conference in New
York City on Tuesday, October 8, 2019 at 11:30 a.m. ET.
A live webcast of each presentation will be available under
“Events & Presentations” in the Investors section of the
Moderna website at https://investors.modernatx.com/. A replay of
each webcast will be archived on Moderna’s website for 30 days
following the presentations.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that have a therapeutic or preventive
benefit with the potential to address a broad spectrum of diseases.
Moderna’s platform builds on continuous advances in basic and
applied mRNA science, delivery technology and manufacturing,
providing the Company the capability to pursue in parallel a robust
pipeline of new development candidates. Moderna is developing
therapeutics and vaccines for infectious diseases, immuno-oncology,
rare diseases and cardiovascular diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
and Merck, Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense and the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been ranked in the top ten of Science’s
list of top biopharma industry employers for the past four years.
To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190925005182/en/
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024